Scott  Hutton net worth and biography

Scott Hutton Biography and Net Worth

CEO of Biodesix
Scott Hutton has served as our President, Chief Executive Officer and Director since January 2020, and previously held the role of Chief Operating Officer from March 2018 to December 2019. Additionally, Mr. Hutton has served on the board of Eximis Surgical since February 2018 and was an Observer on the Board of Directors of Aqueduct Critical Care from September 2014 to January 2017. Mr. Hutton joined Biodesix from Spectranetics Corp (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions (now part of Royal Philips (NYSE: PHG)), where he served as Senior Vice President and General Manager of the Vascular Intervention division from January 2017 to December 2017. Prior to joining Spectranetics, Mr. Hutton held several positions of increasing responsibility, including Vice President and General Manager, at Medtronic plc (NYSE: MDT), a global healthcare products company and manufacturer of medical devices and supplies, over a period of 16 years. From April 2012 to January 2017, Mr. Hutton was Vice President and General Manager of Neurosurgery, where he oversaw the operations of the approximately $1 Billion Neurosurgery Business Unit. From 2008 to 2012, he grew from Senior Director of Global Marketing to Vice President and Business Leader of the Surgical Navigation and Intra-Operative Imaging Business. Mr. Hutton holds a B.A. in Health and Kinesiology from Purdue University. In July 2011, Mr. Hutton received the Medtronic Wallin Leadership Award for his focus on talent development, business performance, and his personal and intentional demonstration of leadership.

What is Scott Hutton's net worth?

The estimated net worth of Scott Hutton is at least $704,980.48 as of August 12th, 2024. Mr. Hutton owns 518,368 shares of Biodesix stock worth more than $704,980 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Hutton may own. Additionally, Mr. Hutton receives an annual salary of $614,920.00 as CEO at Biodesix. Learn More about Scott Hutton's net worth.

How old is Scott Hutton?

Mr. Hutton is currently 52 years old. There are 3 older executives and no younger executives at Biodesix. Learn More on Scott Hutton's age.

What is Scott Hutton's salary?

As the CEO of Biodesix, Inc., Mr. Hutton earns $614,920.00 per year. Learn More on Scott Hutton's salary.

How do I contact Scott Hutton?

The corporate mailing address for Mr. Hutton and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Scott Hutton's contact information.

Has Scott Hutton been buying or selling shares of Biodesix?

Scott Hutton has not been actively trading shares of Biodesix during the last quarter. Most recently, Scott Hutton sold 963 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $1.57, for a transaction totalling $1,511.91. Following the completion of the sale, the chief executive officer now directly owns 518,368 shares of the company's stock, valued at $813,837.76. Learn More on Scott Hutton's trading history.

Who are Biodesix's active insiders?

Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.

Are insiders buying or selling shares of Biodesix?

During the last twelve months, Biodesix insiders bought shares 3 times. They purchased a total of 315,000 shares worth more than $393,500.00. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 106,909 shares worth more than $189,592.09. The most recent insider tranaction occured on November, 20th when Director Jack W Schuler bought 200,000 shares worth more than $234,000.00. Insiders at Biodesix own 69.2% of the company. Learn More about insider trades at Biodesix.

Information on this page was last updated on 11/20/2024.

Scott Hutton Insider Trading History at Biodesix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2024Sell963$1.57$1,511.91518,368View SEC Filing Icon  
8/9/2024Sell2,781$1.60$4,449.60519,331View SEC Filing Icon  
5/9/2024Sell3,764$1.48$5,570.72483,780View SEC Filing Icon  
2/12/2024Sell29,708$1.66$49,315.28465,011View SEC Filing Icon  
2/9/2024Sell34,682$1.92$66,589.44494,719View SEC Filing Icon  
11/9/2023Sell1,882$1.27$2,390.14331,311View SEC Filing Icon  
8/9/2023Sell6,893$1.39$9,581.27324,902View SEC Filing Icon  
5/9/2023Sell9,934$1.57$15,596.38244,570View SEC Filing Icon  
2/9/2023Sell16,278$1.80$29,300.40199,726View SEC Filing Icon  
11/9/2022Sell7,690$1.04$7,997.60112,097View SEC Filing Icon  
8/9/2022Sell13,634$2.53$34,494.0275,009View SEC Filing Icon  
5/10/2022Sell13,278$1.83$24,298.7443,866View SEC Filing Icon  
11/17/2021Buy3,000$6.46$19,380.00View SEC Filing Icon  
See Full Table

Scott Hutton Buying and Selling Activity at Biodesix

This chart shows Scott Hutton's buying and selling at Biodesix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biodesix Company Overview

Biodesix logo
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Read More

Today's Range

Now: $1.39
Low: $1.31
High: $1.40

50 Day Range

MA: $1.53
Low: $1.19
High: $1.78

2 Week Range

Now: $1.39
Low: $1.11
High: $2.21

Volume

69,102 shs

Average Volume

208,776 shs

Market Capitalization

$202.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15